Bank Of America Corp Vor Biopharma Inc. Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in Vor Biopharma Inc. stock. As of the latest transaction made, Bank Of America Corp holds 5,871 shares of VOR stock, worth $5,107. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,871

Previous 25,165 76.67%

Holding current value

$5,107

Previous $25,000 84.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.7 - $1.1 $13,505 - $21,223	-19,294 Reduced 76.67%	5,871 $4,000
Q2 2024 Aug 14, 2024	SELL	$1.0 - $2.2 $3,477 - $7,649	-3,477 Reduced 12.14%	25,165 $25,000
Q1 2024 May 15, 2024	SELL	$1.8 - $2.85 $44,818 - $70,962	-24,899 Reduced 46.5%	28,642 $67,000
Q4 2023 Feb 14, 2024	BUY	$1.66 - $2.63 $57,759 - $91,510	34,795 Added 185.61%	53,541 $120,000
Q2 2023 Aug 14, 2023	SELL	$3.09 - $5.33 $109,942 - $189,641	-35,580 Reduced 65.49%	18,746 $57,000
Q1 2023 May 12, 2023	BUY	$4.68 - $6.96 $235,797 - $350,672	50,384 Added 1278.13%	54,326 $292,000
Q4 2022 Feb 10, 2023	BUY	$3.77 - $7.43 $8,456 - $16,665	2,243 Added 132.02%	3,942 $26,000
Q3 2022 Nov 14, 2022	BUY	$3.9 - $5.52 $951 - $1,346	244 Added 16.77%	1,699 $7,000
Q2 2022 Aug 12, 2022	SELL	$3.89 - $6.44 $24,168 - $40,011	-6,213 Reduced 81.03%	1,455 $7,000
Q1 2022 May 16, 2022	SELL	$6.04 - $12.23 $38,607 - $78,174	-6,392 Reduced 45.46%	7,668 $47,000
Q4 2021 Feb 08, 2022	SELL	$11.32 - $18.02 $70,059 - $111,525	-6,189 Reduced 30.56%	14,060 $163,000
Q3 2021 Nov 15, 2021	BUY	$12.24 - $20.38 $15,997 - $26,636	1,307 Added 6.9%	20,249 $318,000
Q2 2021 Sep 13, 2021	BUY	$18.65 - $38.78 $353,268 - $734,570	18,942 New	18,942 $353,000

Others Institutions Holding VOR

# of Institutions

Shares Held

41.2M

Call Options Held

9.3K

Put Options Held

100

View Full List

About Vor Biopharma Inc.

Ticker VOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,056,300
Market Cap $33.1M
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...

More about VOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Vor Biopharma Inc. Transaction History